Track topics on Twitter Track topics that are important to you
The primary objective of the study is to evaluate the safety and tolerability of flexible dosages of paliperidone ER as compared with placebo in patients with schizophrenia who are 65 years of age or older. The primary objective of the open-label extension is the long-term assessment of safety and tolerability of paliperidone ER in patients diagnosed with schizophrenia.
Paliperidone is being developed as a new therapeutic agent for the treatment of schizophrenia. The ER formulation of paliperidone was developed to deliver paliperidone at a relatively constant rate over a 24-hour period to improve the tolerability profile and decrease the potential for orthostatic hypotension. Typically, elderly persons with schizophrenia respond well to antipsychotic drugs. However, medications should be administered cautiously and usually at lower starting dosages than those prescribed for younger patients, with care taken to balance efficacy and tolerability. Flexible dosages of paliperidone ER have been chosen for this study to better achieve this balance and more closely mimic clinical practice. This is a multicenter, double-blind (neither the patient nor the physician will know if placebo or drug is being given and at what dose), randomized (patients will be assigned to different treatment groups based solely on chance), placebo-controlled, parallel-arm study. The primary purpose of the study is to evaluate the safety and tolerability of flexible doses of paliperidone ER in patients with schizophrenia who are 65 years of age or older. The study consists of a screening phase of up to 5 days, a 6-week double-blind treatment phase, and an optional 24-week open-label treatment phase. For administrative purposes, the screening and the double-blind treatment phases are referred to as R076477-SCH-302 and the open-label treatment phase is named R076477-SCH-702. Patients will be randomly assigned to receive paliperidone ER or placebo. At the time patients enter the double-blind period, they must be hospitalized for a minimum of 14 full days. Those patients who receive paliperidone ER will start at a dosage of 6 mg taken daily, which may be titrated up to a maximum of 12 mg or down to a minimum of 3 mg daily based on the patient's safety and tolerability of the drug. Patients who complete the 6 weeks of double-blind treatment, or who finish at least 21 days of treatment and discontinue because of lack of efficacy, may enter the 24-week open label treatment phase. While patients are hospitalized, efficacy will be assessed twice during the first week and at the end of the second week. Efficacy will be evaluated throughout the 6-week double-blind phase by completion of the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale - Severity (CGI-S), Personal and Social Performance Scale (PSP), Schizophrenia Quality of Life Scale, Revision 4 (SQLS-R4), and Sleep Visual Analog Scale (VAS) during the double-blind treatment phase. The efficacy variable will be measured by the change from baseline score for PANSS, CGI S, SQLS-R4, Sleep VAS, and PSP. Safety will be monitored throughout the study based on incidence of adverse events; measurement of extrapyramidal symptoms using 3 rating scales (Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Rating Scale [BARS], Simpson-Angus Rating Scale [SAS]); measurement of vital signs (blood pressure, heart rate); electrocardiograms; and clinical laboratory tests. Double-blind phase: paliperidone ER will be flexibly dosed in the range 3 to 12 mg (3, 6, 9, or 12 mg/day) orally once a day or matching placebo, for 6 weeks.
Open-label phase: The starting dose is 6 mg/day for 7 days; thereafter, flexible oral dosage of paliperidone ER (3, 6, 9, or 12 mg/day) for 24 weeks.
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Published on BioPortfolio: 2014-07-23T21:52:00-0400
The purpose of this study is to evaluate the long-term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to d...
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
The purpose of this study is to evaluate the concentration of paliperidone in the blood after intramuscular injection in upper arm (deltoid muscle) or in the buttock (gluteal muscle) in pa...
The purpose of this study is to explore efficacy, tolerability and safety of paliperidone Extended Release (ER) in 250 schizophrenia patients who started treatment with paliperidone ER in ...
Primary objective: To examine whether the switch to paliperidone ER from risperidone improves cognitive function in stabilized patients with schizophrenia. Secondary objectives: To compar...
The aim was to compare adherence to antipsychotics (APs), healthcare resource utilization (HRU), and costs before and after once-every-3-months paliperidone palmitate (PP3M) initiation in patients wit...
The aim of this article was to describe and compare treatment patterns, health care resource utilization (HRU), and health care costs before and after transition in veterans with schizophrenia who wer...
Our ability to predict and prevent homicides committed by individuals with schizophrenia is limited. Cognitive impairments are associated with poorer functional outcome in schizophrenia, possibly also...
Patients with schizophrenia commonly suffer from impairments in various aspects of cognition. These deficits were shown to have detrimental effects on daily life functioning and might also impair car ...
A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.
A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.
A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...